TNFSF10 and glioblastoma: Moreover, in xenografted human GBM, the activation status of the PTEN-Akt-mTOR pathway distinguishes the inherent TRAIL-sensitive tumors from those sensitized by rapamycin, an mTOR inhibitor [57].